Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors-Reference-Cited by-同舟云学术

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Published:2020-05 Issue:5 Volume:31 Page:626-633
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Isakoff S.J.,Tabernero J.,Molife L.R.,Soria J.-C.,Cervantes A.,Vogelzang N.J.,Patel M.R.,Hussain M.,Baron A.,Argilés G.,Conkling P.R.,Sampath D.,Maslyar D.,Patel P.,Chan W.,Gendreau S.,Musib L.,Xu N.,Ma H.,Lin K.,Bendell J.

Funder

Genentech, Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference19 articles.

1. Targeting the PI3K-AKT-mTOR signaling network in cancer;Khan;Chin J Cancer,2013

2. AKT/PKB signaling: navigating the network;Manning;Cell,2017

3. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines;Garcia;Leuk Res,2009

4. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer;Wallin;Sci Transl Med,2010

5. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status;Wang;Int J Cancer,2008

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond;Critical Reviews in Oncology/Hematology;2024-08

2. Landscape of targeted therapies for advanced urothelial carcinoma;Exploration of Targeted Anti-tumor Therapy;2024-06-21

4. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities;Pharmacological Research;2024-04

5. MTCH2 stimulates cellular proliferation and cycles via PI3K/Akt pathway in breast cancer;Heliyon;2024-03